MBX Biosciences (MBX) is testing a weekly shot called canvuparatide in patients with chronic hypoparathyroidism, a condition in which the body doesn't produce enough parathyroid hormone. Parathyroid hormone is necessary for regulating the levels of calcium in the body.
In the study, 63% of canvuparatide recipients made it 12 weeks without needing parathyroid hormone, or PRN, rescue therapy. This means their calcium levels remained at normal levels. In the open-label extension study — in which all patients knowingly receive the drug — 79% of patients were responders at six months.
Based on the results, MBX Biosciences is now planning a Phase 3 study for 2026.
